Document:

Exhibit 4.4
SPRINGWORKS THERAPEUTICS, INC.
​
AMENDMENT TO THE
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT
​
This Amendment to the Amended and Restated Investors’ Rights Agreement (this “Amendment”) is made as of February 25, 2021 by and among SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”), and certain holders of outstanding Registrable Securities.
Reference is hereby made to that certain Amended and Restated Investor Rights Agreement, dated August 30, 2019, by and among the Company and the signatories thereto, as amended to date (the “Rights Agreement”).  Capitalized terms used herein that are not otherwise defined shall have the meaning ascribed thereto in the Rights Agreement.
WHEREAS, Section 6.6 of the Rights Agreement provides that any term of the Rights Agreement may be amended, modified or terminated with the written consent of the Company and the holders of at least a majority of the Requisite Parties, provided that the written consent of any particular Investor need not be obtained in connection with such amendment, modification or termination of any term of the Rights Agreement so long as such amendment, modification or termination applies to all Investors in the same fashion;
​
NOW THEREFORE, for good and valuable consideration, the receipt of and sufficiency of which is hereby acknowledged, each of the Requisite Parties and the Company agree as follows:
​
1.         The undersigned Investors, together comprising the Requisite Parties, hereby agree to amend and restate Section 2.13 of the Rights Agreement in its entirety, to read as follows:
​
“2.13    Termination of Registration Rights.  The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Subsections 2.1 or 2.2 shall terminate upon the earliest to occur of:
​
(a)     immediately before the closing of a Deemed Liquidation Event, as such term is defined in the Company’s Certificate of Incorporation;
​
(b)     as to such Holder, such earlier time after the IPO at which all shares of Registrable Securities held or entitled to be held upon conversion by such Holder may immediately be sold under SEC Rule 144 without regard to time or volume limitations; and
​
(c)     the fourth anniversary of the IPO.
​
2.         Except as expressly amended, modified, supplemented or waived hereby, the provisions of the Rights Agreement are and will remain in full force and effect.
​
​

​
3.         This Amendment may be executed in any number of counterparts, each of which shall constitute one agreement binding on all the parties to the Rights Agreement.
​
4.         This Amendment shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, exclusive of its choice of laws and conflicts of laws rules.
​
NO ANNOUNCEMENT HAS BEEN MADE CONCERNING THE FILING OF THE REGISTRATION STATEMENT OR THE OFFERING. ACCORDINGLY, THIS INFORMATION MUST BE KEPT STRICTLY CONFIDENTIAL.
[Signature page follows]
​
​
​

2

​
IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first set forth above.
​
		SPRINGWORKS THERAPEUTICS, INC.

	​
	​

	​
	​

		By:
	/s/ Francis I. Perier, Jr.

			Name:
	Francis I. Perier, Jr.

			Title:
	Chief Financial Officer

​
​
​
​

Signature Page to SpringWorks Therapeutics, Inc. Waiver and IRA Amendment

​
IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the date first set forth above.
​
		ORBIMED PRIVATE INVESTMENTS VI, LP

	​
	​

		By:
	OrbiMed Capital GP VI LLC, its General Partner

		
			By:
	: OrbiMed Advisors LLC, its Managing Member

	​
	​

		By:
	/s/ Carl Gordon

		
			Name:
	Carl Gordon

		
			Title:
	Member

		
	​
	​

	​
	BC SW, LP

		
		By:
	Bain Capital Life Sciences Investors, LLC its general partner

		
		By:
	/s/ Jeff Schwartz

		
			Name:
	Jeff Schwartz

		
			Title:
	Managing Director

​
​
​
​

Signature Page to SpringWorks Therapeutics, Inc. Waiver and IRA Amendment

​
		PFIZER INC.

	​
	​

		By:
	/s/ Barbara Dalton

	​
	​

			Name:
	Barbara Dalton

	​
	​

			Title:
	Vice President

	​
	​

		
	​
	PFIZER INC.

	​
	​

		By:
	/s/ Barbara Dalton

	​
	​

			Name:
	Barbara Dalton

	​
	​

			Title:
	President

​

Signature Page to SpringWorks Therapeutics, Inc. Waiver and IRA AmendmentExhibit 10.5
SPRINGWORKS THERAPEUTICS, INC. 
AMENDED AND RESTATED
NON-EMPLOYEE DIRECTOR COMPENSATION POLICY
This Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of dated February 23, 2021 (the “Effective Date”) of SpringWorks Therapeutics, Inc., a Delaware corporation (the “Company”) amends and restates the previous Non-Employee Director Compensation Policy which became effective as of the effective time of the registration statement for the Company’s initial firm commitment underwritten public offering of equity securities on September 12, 2019. The purpose of the Policy is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company. This Policy and will apply to all non-employee directors of the Board (such directors, the “Eligible Directors”) of the Company (the “Board”). In furtherance of this purpose, except as otherwise provided in any written agreement between the Company and an Eligible Director, all Eligible Directors shall be paid compensation for services provided to the Company as set forth below:
Cash Retainers
Annual Retainer for Board Membership: $40,000 for general availability and participation in meetings and conference calls of our Board. No additional compensation for attending individual Board meetings.
Additional Annual Retainer for Non-Executive Chair of the Board: $30,000
​
​
Additional Annual Retainers for Committee Membership:
​
	​

	​

	​

	​

	​

	Audit Committee Chairperson:
	    
	$
	15,000
	​

	​
	​
	​
	​
	​

	Audit Committee member:
	​
	$
	7,500
	​

	​
	​
	​
	​
	​

	Compensation Committee Chairperson:
	​
	$
	10,000
	​

	​
	​
	​
	​
	​

	Compensation Committee member:
	​
	$
	5,000
	​

	​
	​
	​
	​
	​

	Nominating and Corporate Governance Committee Chairperson:
	​
	$
	8,000
	​

	​
	​
	​
	​
	​

	Nominating and Corporate Governance Committee member:
	​
	$
	4,000
	​

	​
	​
	​
	​
	​

	Research and Development Committee Chairperson
	​
	$
	10,000
	​

	​
	​
	​
	​
	​

	Research and Development Committee member
	​
	$
	5,000
	​

​
Note: Chair and committee member retainers are in addition to retainers for members of the Board of Directors.
​
​

All cash retainers will be paid quarterly, in arrears, or upon the earlier of resignation or removal of the Eligible Director. Cash retainers owing to Eligible Directors shall be annualized, meaning that with respect to Eligible Directors who join the Board during the calendar year.
For purposes of this Policy, “Value” means with respect to any award of stock options the grant date fair value of the option (i.e., Black-Scholes Value) determined in accordance with the reasonable assumptions and methodologies employed by the Company for calculating the fair value of options under ASC 718.
Equity Retainers
Initial Equity Grant: Upon the Effective Date, each Eligible Director serving as of such date shall receive a one-time equity grant of an option to purchase that number of shares of Common Stock that has a Value equivalent to $840,000, with 80% of such value to be provided in stock options for shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”) and 20% of such value to be provided in restricted stock awards, representing shares of the Company’s Common Stock. Such initial equity grant shall vest in equal annual installments for three years starting from the Eligible Director’s commencement of service on the Board any of the above committees, as applicable, subject to the Eligible Director’s continued service on the Board through each such date. For each Eligible Director joining the Board after the Effective Date, upon his or her initial appointment to the Board, each such Eligible Director shall receive a one-time equity grant of an option to purchase that number of shares of Common Stock that has a Value equivalent to $840,000. Such initial equity grant shall vest in equal annual installments for three years starting from the Eligible Director’s commencement of service on the Board any of the above committees, as applicable, subject to the Eligible Director’s continued service on the Board through each such date.
Annual Equity Grant: Immediately following each annual meeting of the Company’s stockholders, each continuing Eligible Director will receive an annual equity grant of an option to purchase that number of shares of Common Stock that has a Value equivalent to $420,000, with 80% of such value to be provided in stock options for shares of the Company’s Common Stock and 20% of such value to be provided in restricted stock awards, representing shares of the Company’s Common Stock. Such annual equity grant shall vest on the earlier of the one-year anniversary of the grant date and the Company’s next annual meeting of stockholders, subject to the Eligible Director’s continued service on the Board through such date.
All of the foregoing option grants will become immediately exercisable upon the death, disability of an Eligible Director or upon a Sale Event (as defined in the Company’s 2019 Stock Option and Incentive Plan). In addition, Eligible Directors will have until the earlier of one year following cessation of service as a director or the original expiration date of the option to exercise the option (to the extent vested at the date of such cessation), provided that the Eligible Director has not been removed for cause.
Any stock option granted to an Eligible Director pursuant to this Policy will be granted at an exercise price equal to the Fair Market Value of a share of Common Stock on the date of grant (as defined in the Company’s 2019 Stock Option and Incentive Plan).
Expenses
The Company shall reimburse all reasonable out-of-pocket expenses incurred by Eligible Directors in attending Board and committee meetings.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00322-of-00352.parquet"}]]